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1. Introduction 
Mitochondria are essential cytoplasmic organelles generating cellular energy in the form of 
adenosine triphosphate by oxidative phosphorylation. Most cells contain hundreds of 
mitochondria, each of which has several mitochondrial DNA (mtDNA) copies, so each cell 
contains thousands of mtDNA copies. mtDNA has a very high mutation rate, and when a 
mutation occurs the cell initially contains a mixture of wild-type and mutant mtDNAs, a 
situation known as heteroplasmy. If the percentage of mutant mtDNA increases enough that 
the cell’s ATP production falls below the level needed for normal cell function, disease 
symptoms appear and become progressively worse. A wide variety of diseases—such as 
Parkinson’s disease (PD), Alzheimer’s disease (AD), and cancer—are reportedly linked to 
mitochondrial dysfunction, and it is clear that mitochondrial diseases encompass an 
extraordinary assemblage of clinical problems (Wallace 1999; Vila and Przedborski 2003; 
Taylor and Turnbull 2005). 
Although mtDNA mutations have been reported to be related both to a wide variety of 
diseases and aging (Lin et al. 1992; Schoffner et al. 1993; Kosel et al. 1994; Mayr-Wohlfart et al. 
1996; Schnopp et al. 1996; Simon et al. 2000; Tanaka et al. 2002; Dawson and Dawson 2003; 
Ross et al. 2003; Lustbader et al. 2004; Niemi et al. 2005; Alexe et al. 2007; Fuku et al. 2007; 
Chinnery et al. 2008; Kim et al. 2008; Maruszak et al. 2008; Feder et al. 2008), there are few 
reports regarding the relations between all mtDNA mutations and either disease patients or 
centenarians. The previous reports have also focused on mutations causing amino acid 
replacements in mitochondrial proteins and, although mitochondrial functions can of course 
be affected directly by amino acid replacements, they can also be affected indirectly by 
mutations in mtDNA control regions. It is therefore important to examine the relations 
between all mtDNA mutations and disease patients or centenarians. 
In the article reported here the relations between Japanese PD patients and their mitochondrial 
single nucleotide polymorphism (mtSNP) frequencies were analyzed using a method based on 
radial basis function (RBF) networks (Poggio and Girosi 1990; Wu and McLarty 2000) and a 
modified method based on RBF network predictions (Takasaki 2009). In addition, the relations 
between the haplogroups of the PD patients and those of the other four classes of people 
(centenarians, AD patients, T2D patients, and healthy non-obese young males) are also 
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described using the same analysis method. The results described here are quite different from 
those reported previously (Saxena et al. 2006; Alexe et al. 2007; Fuku et al. 2007; Bilal et al. 2008).  
2. Materials and methods 
2.1 mtSNPs 
We used complete mtDNA sequences available in GiiB Human Mitochondrial Genome 
Polymorphism Database (http://mtsnp.tmig.or.jp/mtsnp). The mtSNPs used were those in 
96 Japanese PD patients (43 males and 53 females), 96 Japanese centenarians (30 males and 
66 females), 96 Japanese AD patients (20 males and 76 females), 96 Japanese type 2 diabetes 
(T2D) patients (54 males and 42 females), and 96 Japanese healthy non-obese young males 
(Tanaka et al. 2004). 
2.2 RBF-based method of mtSNP classification 
A RBF network is an artificial network used in supervised learning problems such as 
regression, classification, and time series prediction. In supervised learning a function is 
inferred from examples (training set) that a teacher supplies. The elements in the training set 
are paired values of the independent (input) variable and dependent (output) variable. 
The RBF network shown in Fig. 1 was learned from the training set as the mtSNPs of the PD 
patients were regarded as correct and the mtSNPs of other four classes of people 
(centenarians, AD patients, T2D patients, and healthy non-obese young males) were 
regarded as incorrect. Similarly, in the mtSNP classification for the centenarians the mtSNPs 
of the centenarians are regarded as correct and those of the other four classes are regarded 
as incorrect. The mtSNPs of the AD patients, T2D patients, and healthy non-obese young 
males were also classified this way.  
The mitochondrial genome sequences of the PD patients were partitioned into two sets: 
training data comprising the sequences of 64 of the PD patients, and validation data 
comprising the sequences of the other 32 PD patients. The training and validation steps are 
described in detail elsewhere (Takasaki et al. 2006).  
2.3 Modified classification method based on probabilities predicted by the RBF 
network 
Since a RBF network can predict the probabilities that persons with certain mtSNPs belong 
to certain classes (e.g., PD patients, centenarians, AD patients, T2D patients, or healthy non-
obese young males), these predicted probabilities are used to identify mtSNP features. By 
examining the relations between individual mtSNPs and the persons with high predicted 
probabilities of belonging to one of these classes, we are able to identify other mtSNPs 
useful for distinguishing between the members in different classes. A modified classification 
method based on the probabilities predicted by the RBF network was thus carried out in the 
following way (Takasaki 2009). 
1. Select the analysis target class (i.e., PD patients, centenarians, AD patients, T2D 
patients, or healthy non-obese young males). 
2. Rank individuals according to their predicted probabilities of belonging to the target 
class. 
3. Either select individuals whose probabilities are greater than a certain value or select 
the desired number of individuals from the top, and set them as a modified cluster.  
www.intechopen.com
 
Mitochondrial Haplogroups Associated with Japanese Parkinson’s Patients  
 
559 
3
2
3
1
3 3134
3
4
2
3
4
2
3
4
4
3
3 2314
μ1,1 σ1,1
μ1,䠎σ1,䠎
μ1,SNP σ1,SNP
μ䠎,1 σ䠎,1
μ䠎,SNP σ䠎,SNP
μ䠎,䠎σ䠎,䠎
μｍ,1 σｍ,1
μｍ,䠎σｍ,䠎
μｍ,SNP σｍ,SNP
----
----
----
----------
----------
----------
----------
---------------------------------
---------------------------------
---------------------------------
---------------------------------
---------------------------------
---------------------------------
---
XTN   ------------ X5 X4 X3 X2 X1
f(X) 1 ---- 10101
Input layer Hidden layer Output layer
w1
w2
wm
M1σ䠍
M䠎 σ䠎
Mm σm
1
2
3
TSNP
 
Fig. 1. RBF network representation of the relations between individual mtSNPs and the PD 
patients. The input layer is the set of mtSNP sequences represented numerically (A, G, C, 
and T are converted to 1, 2, 3, and 4). The hidden layer classifies the input vectors into 
several clusters depending on the similarities of individual input vectors. The output layer is 
determined depending on which analysis is carried out. In the case of PD patients, 1 
corresponds to PD patients and 0 corresponds to other four classes of people. In the case of 
centenarians, 1 corresponds to centenarians and 0 corresponds to other four classes of 
people. The AD patients, T2D patients, and healthy non-obese young males are also carried 
out in similar way. Xi : i-th input vector, TN : maximum number of vectors (in this example, 
TN=320 (64x5)), TSNP : maximum number of mtSNPs (in this example, TSNP =562), Mm: the 
location vector, m: the number of basis functions, µ: basis function, σ: standard deviation, wi: 
i-th weighting variable, f(X): weighted sum function.  
3. Results and discussion 
3.1 Associations between haplogroups and the mtSNPs of the PD patients  
When the mtSNPs of the PD patients were classified by the RBF-based method described 
above, ten mtSNP clusters were obtained. The average predicted probabilities of these 
clusters for becoming the PD patients were respectively 63%, 62.5%, 52.9%, 30%, 29.4%, 
15.4%, 7.7%, 4.3%, 3.4% and 0%. Then the 15 individuals with the highest probabilities of 
becoming PD patients were selected using the modified classification method, and their 
nucleotide distributions at individual mtDNA positions were examined. After that, the 
relations between Asian/Japanese haplogroups and the mtSNPs for the PD patients were 
examined (Herrnstadt et al. 2002; Kong et al. 2003; Tanaka et al. 2004). The associations 
between the haplogroups and mtSNPs for the PD patients are shown in Fig. 2. The features 
of associations for the PD patients were L3-M-M7b2 (33%), L3-M-G2a (27%), L3-N-B4e 
(13%), B5b (13%), and N9a (7%).  
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489T>C (10/5) 8701A>G (10/5)
10400C>T (10/5) 9540T>C (10/5)
14783T>C (10/5) 10398A>G (12/3)
15043G>A (10/5) 10873T>C (10/5)
15301G>A (10/5)
16362T>C (5/10) 6455C>T (6/9)
709G>A (6/9) 9824T>C (6/9) 16519T>C (7/8)
4833A>G (4/11) 199T>C (6/9)
5108T>C (4/11) 4071C>T (4/11) 12705C>T (11/4) 5417G>A (1/14)
14569G>A (4/11) 150C>T (6/9) 16223C>T (11/4) 150C>T (6/9)
16519T>C (7/8) 4048G>A (6/9) 16519T>C (7/8) 5231G>A (1/14)
5601C>T (4/11) 4164A>G (5/10) 12358A>G (2/13)
13563A>G (4/11) 5351A>G (5/10) 16217T>C (2/13) 709G>A (6/9) 12372G>A (1/14)
7600G>A (4/11) 5460G>A (6/9) 827A>G (2/13) 8584G>A (2/13) 16257C>A (1/14)
9377A>G (4/11) 6680T>C (5/10) 15535C>T (2/13) 9950T>C (2/13) 16261C>T (1/14)
9575G>A (5/10) 7684T>C (5/10) 146T>C (2/13) 10398A>G (12/5)
14200T>C (4/11) 7853G>A (4/11) 16140T>C (2/13)
16278C>T (4/11) 12405C>T (5/10) 204T>C (2/13) (1/15: 7%)
12811T>C (5/10) (2/15: 13%) 1598G>A (2/13)
16297T>C (5/10) 12361A>G (2/13)
(4/15: 27%) 10345T>C (5/10) 15223C>T (2/13)
16519T>C (7/8) 15508C>T (2/13)
15851A>G (2/13)
15927G>A (2/13)
(5/15: 33%) 16243T>C (2/13)
(2/15: 13%)
L3
M
G2a
N
B4c1B4e
N9a
M7b2
B5b
 
(A) PD patients 
 
　　　　　　L3
489T>C (13/2) 8701A>G (11/4)
10400C>T (11/4) 9540T>C (11/4)
14783T>C (11/4) 10398A>G (15/0)
15043G>A (11/4) 10873T>C (10/5)
15301G>A (11/4)
　　　　　　M
                   N
6455C>T (7/8) 16362T>C (5/15)
9824T>C (7/8) 16519T>C (4/11) 16519T>C (4/11)
199T>C (10/5) 4883C>T (4/11) 12705C>T (12/3)
4071C>T (7/8) 5178C>A (4/11) 16223C>T (12/3)
150C>T (7/8) 16519T>C (4/11)
4048G>A (6/9)                     D 709G>A (3/12)
4164A>G (6/9) 8584G>A (3/12)
5351A>G (6/9) 3010G>A (4/11) 9950T>C (3/12)
5460G>A (6/9) 8414C>T (4/11) 10398A>G (15/0)
6680T>C (6/9) 14668C>T (4/11) 16140T>C (3/12)
7684T>C (6/9) 204T>C (4/11)
7853G>A (6/9) 8020G>A (5/10) 1598G>A (3/12)
12405C>T (6/9) 1382A>C (4/11) 8829C>T (3/12)
12811T>C (6/9) 8964C>T (4/11) 12361A>G (3/12)
16297T>C (6/9) 9824T>A (4/11) 15223C>T (3/12)
16129G>A (6/9) 15508C>T (3/12)
10345T>C (6/9) 15524A>G (3/12) 15662A>G (3/12)
16298T>C (6/9) 8251G>A (4/11) 15851A>G (3/12)
10104C>T (4/11) 15927G>A (3/12)
M7b2 199T>C (10/5) 16243T>C (3/12)
(6/15: 40%)
D4b2a B5b
(4/15: 27%) (3/15: 20%)
(B) Centenarians  
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489T>C (8/7) 8701A>G (8/7)
10400C>T (8/7) 9540T>C (8/7)
14783T>C (8/7) 10398A>G (8/7)
15043G>A (8/7) 10873T>C (8/7)
15301G>A (8/7)
16362T>C (8/7)
709G>A (11/4) 16519T>C (11/4)
4833A>G (8/7)
5108T>C (8/7) 12705C>T (11/4) 5417G>A (4/11)
14569G>A (8/7) 16223C>T (12/3) 5147G>A (4/11)
16519T>C (11/4) 16519T>C (11/4) 10607C>T (4/11)
5601C>T (8/7) 16217T>C (3/12) 11016G>A (4/11)
13563A>G (8/7) 15346G>A (3/12) 13183A>G (4/11)
7600G>A (8/7) 3497C>T (3/12) 14893A>G (4/11)
9377A>G (8/7) 709G>A (11/4)
9575G>A (8/7)
14200T>C (8/7)       (4/15: 27%)
16278C>T (8/7)      (3/15: 20%)
   (8/15: 53%)
L3
M
G2a
N
B4c1
N9b1
 
(C) AD patients 
 
          L3
489T>C (7/8) 8701A>G (7/8)
10400C>T (7/8) 9540T>C (7/8)
14783T>C (7/8) 10398A>G (11/4)
15043G>A (7/8) 10873T>C (7/8)
15301G>A (7/8)
          M
           N
4715A>G (2/13) 16362T>C (5/10)
7196C>A (2/13) 16519T>C (9/6)
8584G>A (6/9) 709G>A (6/9) 16519T>C (9/6) 12705C>T (8/7)
15487A>T (2/13) 4833A>G (2/13) 4883C>T (2/13) 16223C>T (9/6)
16298T>C (2/13) 5108T>C (2/13) 5178C>A (2/13) 16519T>C (9/6)
6179G>A (2/13) 14569G>A (2/13)
8684C>T (2/13) 16519T>C (9/6)           D 3970C>T (3/12) 709G>A (6/9)
14470T>C (4/11) 13928G>C (3/12) 8584G>A (6/9)
16319G>A (5/10)           G 3010G>A (2/13) 16304T>C (3/12) 9950T>C (4/11)
16519T>C (9/6)      (2/15: 13%) 8414C>T (2/13) 6392T>C (3/12) 10398A>G (11/4)
6719T>C (2/13) 14668C>T (2/13) 10310G>A (3/12) 16140T>C (5/10)
16311T>C (2/13) 6962G>A (2/13) 204T>C (3/12)
          D4 10609T>C (2/13) 1598G>A (3/12)
        M8a1      (2/15: 13%) 12406G>A (3/12) 8829C>T (3/12)
    (2/15: 13%) 12882C>T (2/13) 12361A>G (3/12)
15223C>T (3/12)
           F1 15508C>T (3/12)
      (2/15: 13%) 15662A>G (3/12)
15851A>G (3/12)
15927G>A (3/12)
16243T>C (3/12)
          B5b
(3/15: 20%)
(D) T2D patients
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            L3
489T>C (15/0)
10400C>T (15/0)
14783T>C (15/0)
15043G>A (15/0)
            M
16362T>C (15/0)
16519T>C (0/15)
4883C>T (15/0)
5178C>A (15/0)
            D
3010G>A (15/0)
8414C>T (15/0)
14668C>T (15/0)
8701A>G (10/5) 8020G>A (9/6)
4343A>G (5/10)
13104A>G (5/10) 10181C>T (4/11) 8964C>T (5/10)
15518C>T (5/10) 15440T>C (4/11) 9824T>A (5/10)
16278C>T (5/10) 15951A>G (4/11) 15524A>G (5/10)
16319G>A (4/11) 8251G>A (3/12)
          D4g 431C>T (4/11) 10104C>T (3/12)
      (5/15: 33%) 6689C>T (4/11) 199T>C (3/12)
16287C>T (4/11)
16399A>G (3/12)         D4b2a
(3/15: 20%)
      D4b1b
     (4/15: 27%)  
(E) Non-obese young males 
Fig. 2. Associations between haplogroups and the mtSNPs of the 15 persons with the highest 
probabilities of becoming PD patients. This description of associations is based on the 
phylogenetic tree for macrohaplogroups M and N described in Tanaka et al. [26]. The locus 
of mtDNA polymorphism (mmm), the normal nucleotide (rCRS) at the position mmm (NN), 
the mtDNA mutation at that position (NM), the number of the mtDNA mutations at mmm in 
individual clusters (Y), and the number of the normal nucleotides at mmm in individual 
clusters (X) are expressed as mmmNN>NM (Y/X). For example, 489T>C (10/5)  indicates the 
mtDNA locus (489), the normal nucleotide at that position (T), the mutation at that position 
(C), the number of mutations (10), and the number of the normal nucleotides in the cluster 
(5). (B) Centenarians, (C) AD patients, (D) T2D patients, (E) Non-obese young males. 
To compare the mitochondrial haplogroups of the PD patients with those of other classes of 
people, we used the same modified method to examine the relations between the other four 
classes (i.e., centenarians, AD patients, T2D patients, and non-obese young males) and their 
mtSNPs. The associations between the haplogroups and mtSNPs for four classes of Japanese 
people are shown in Fig. 2 B to E. The centenarians were associated haplogroups L3-M-
M7b2 (40%), L3-M-D-D4b2a (27%), and L3-N-B5b (20%); the AD patients were associated 
haplogroups L3-M-G2a (53%), L3-N-B4c1 (20%), and N9b1 (27%); the T2D patients were 
associated haplogroups L3-M-D-D4 (13%), L3-M-M8a1 (13%), G (13%), L3-N-B5b (20%), and 
F1 (13%); and the healthy non-obese young males were associated haplogroups L3-M-D-D4g 
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(33%), D4b2a (20%), and D4b1b (27%). The relations among the haplogroups for these five 
classes of people are listed in Table 1.  
 
Classification
consideration
PD patients Centenarians AD patients T2D patients Non-obese males
M8a1 (13%)
M7b2 (33%) M7b2 (40%)
G (13%)
G2a (27%) G2a (53%)
D4 (13%)
D4b1b (27%)
D4b2a (20%)
D4b2a (27%)
D4g (33%)
B4e (13%)
B5b (13%) B5b (20%) B5b (20%)
B4c1 (20%)
N9a (7%)
N9b1 (27%)
F1 (13%)
M8a1 (4%)
M7a1a (19%)
M7b2 (14%) M7b2 (13%)
G (11%)
G1 (9%)
G1a (14%)
G2a (11%) G2a (17%)
D4 (19%) D4 (47%)
D4a (15%)
D4b1b (24%)
D4b2 (35%)
D4b2a (9%)
D4b2b (16%)
D4g (29%)
D5a (6%)
B4e (5%)
B4c1 (11%)
B5b (5%) B5b (7%) B5b (6%)
N9a (16%) N9a (4%)
N9b1 (9%) N9b1 (6%)
F1 (11%) F1 (6%)
15 persons from
the top
Persons whose
probabilities are
greater than 50%
 
Table 1. The relations among the haplogroups for five classes of people 
In Table 1 we see that the haplogroup Mb2 was common in PD patients and centenarians, 
G2a was common in PD patients and AD patients; and B5b was common in PD patients, 
centenarians, and T2D patients. The haplogroups of the PD patients are therefore different 
from those of the other four classes of people. The results are therefore considered new 
findings. 
Then individuals whose probabilities of becoming PD patients were greater than 50% were 
selected, and the nucleotide distributions of those 37 persons were examined. The 
associations between haplogroups and the mtSNPs of those PD patients are shown in Fig. 3. 
Individuals whose probabilities of becoming PD patients were greater than 50% were 
classified into more haplogroups than were the 15 persons most likely to become PD 
patients. The ratios of the haplogroups M7b2, G2a, B4e, B5b and N9a for the 15 persons most 
likely to become PD patients were respectively changed from 33% to 14%, 27% to 11%, 13% 
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to 5%, 13% to 5%, and 7% to 16%, and new haplogroups M7a1a (19%) and G1a (14%) were 
classified for the persons whose probabilities were greater than 50%. The other four classes 
of people were also examined for the persons whose probabilities were greater than 50%. 
The selected numbers of the four classes were 55 for centenarians, 47 for AD patients, 47 for 
T2D patients, and 17 for healthy non-obese young males. The associations between the 
haplogroups and mtSNPs for four classes of people are shown in Fig. 3 B to E. The 
centenarians were associated haplogroups L3-M-M7b2 (13%), L3-M-D-D4a (15%), D4b2a 
(9%), D4b2b (16%), and L3-N-B5b (7%); the AD patients were associated haplogroups L3-M-
G1 (9%), G2a (17%), L3-M-D-D4 (19%), L3-N-F1 (11%), B4c1 (11%), N9a (4%), and N9b1 
(9%); the T2D patients were associated haplogroups L3-M-M8a1 (4%), G (11%), L3-M-D-D4 
(47%), D5a (6%), L3-N-F1 (6%), B5b (6%), and N9b1 (6%); and the healthy non-obese young 
males were associated haplogorups L3-M-D-D4g (29%), D4b1b (24%), and D4b2 (35%). The 
relations among the haplogroups of the selected persons for the five classes of people are 
also listed in Table 1, where one sees that the individual classes of people were classified 
into more haplogroups when the mtSNP analysis was based on the persons whose 
probabilities were greater than 50% than they were when the analysis was based on the 
highest 15 persons from the top. 
3.2 Comparison with previous works for T2D patients and Centenarians 
Although there is no report regarding the relations between mtSNP haplogroups and PD 
patients but there were a few studies concerning the relations between mtSNP haplogroups 
and T2D patients or centenarians, the differences between previous works and the work 
reported here are discussed based on the mtSNP haplogroups obtained. 
 
489T>C (22/15) 8701A>G (22/15)
10400C>T (22/15) 9540T>C (22/15)
14783T>C (22/15) 10398A>G (25/12)
15043G>A (22/15) 10873T>C (22/15)
15301G>A (22/15)
16362T>C (10/27) 6455C>T (13/24)
709G>A (15/22) 9824T>C (13/24) 16519T>C (20/17)
4833A>G (9/28) 199T>C (7/30) 2626T>C (8/29)
5108T>C (10/27) 4071C>T (4/33) 2772C>T (8/29) 12705C>T (28/9) 5417G>A (6/31)
14569G>A (9/28) 150C>T (18/19) 4386T>C (8/29) 16223C>T (28/9) 150C>T (18/19)
16519T>C (20/17) 8200T>C (5/32) 4048G>A (7/30) 4958A>G (8/29) 16519T>C (20/17) 5231G>A (6/31)
5601C>T (4/33) 15323G>A (5/32) 4164A>G (5/32) 12771G>A (8/29) 12358A>G (7/30)
13563A>G (4/33) 15497G>A (5/32) 5351A>G (5/32) 16209T>C (7/30) 16217T>C (7/30) 709G>A (15/22) 12372G>A (6/31)
7600G>A (4/33) 7867C>T (5/37) 5460G>A (6/31) 14364G>A (8/29) 827A>G (3/34) 8584G>A (2/35) 16257C>A (6/31)
9377A>G (4/33) 150C>T (18/19) 6680T>C (5/32) 16519T>C (20/17) 15535C>T (3/34) 9950T>C (2/35) 16261C>T (8/29)
9575G>A (5/32) 15860A>G (5/32) 7684T>C (5/32) 16324T>C (8/29) 146T>C (2/35) 10398A>G (25/12)
14200T>C (4/33) 16325T>C (5/32) 7853G>A (4/33) 11017T>C (7/30) 16140T>C (2/35)
16278C>T (4/33) 11914G>A (5/32) 12405C>T (5/32) 11084A>G (7/30) 204T>C (3/34) (6/37: 16%)
12811T>C (5/32) (2/37: 5%) 1598G>A (2/35)
16297T>C (5/32) 12361A>G (2/35)
(4/37: 11%) (5/37: 14%) 10345T>C (5/32) (7/37: 19%) 15223C>T (2/35)
16519T>C (20/17) 15508C>T (2/35)
15851A>G (2/35)
15927G>A (2/35)
(5/37: 14%) 16243T>C (2/35)
(2/37: 5%)
L3
M
G2a
N
B4c1B4e
N9a
M7b2
B5b
G1a M7a1a
 
(A) PD patients 
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               L3
489T>C (49/6) 8701A>G (46/9)
10400C>T (47/8) 9540T>C (47/8)
14783T>C (47/8) 10398A>G (53/2)
15043G>A (47/8) 10873T>C (46/9)
15301G>A (47/8)
                M
                 N
6455C>T (8/47) 16362T>C (38/17)
9824T>C (8/47) 16519T>C (28/27) 16519T>C (28/27)
199T>C (18/47) 4883C>T (36/19) 12705C>T (50/5)
4071C>T (9/46) 5178C>A (37/18) 16223C>T (45/10)
150C>T (13/42) 16519T>C (28/27)
4048G>A (8/47)                  D 709G>A (5/50)
4164A>G (8/47) 8584G>A (7/48)
5351A>G (8/47) 3010G>A (34/21) 9950T>C (5/50)
5460G>A (8/47) 8414C>T (34/21) 10398A>G (53/2)
6680T>C (7/48) 14668C>T (34/21) 16140T>C (5/50)
7684T>C (7/48) 204T>C (8/47)
7853G>A (7/48) 152T>C(10/45) 8020G>A (19/36) 1598G>A (4/51)
12405C>T (7/48) 3206C>T(8/47) 1382A>C (17/38) 8829C>T (4/51)
12811T>C (7/48) 14979T>C(8/47) 8964C>T (17/38) 12361A>G (4/51)
16297T>C (7/48) 16129G>A(17/38) 9824T>A (17/38) 15223C>T (4/51)
16129G>A (17/38) 8473T>C(8/47) 15508C>T (4/51)
10345T>C (7/48) 16519T>C(28/27) 15524A>G (5/50) 9296C>T(11/44) 15662A>G (4/51)
16298T>C (9/46) 10410T>C(8/47) 8251G>A (5/50) 16519T>C(28/27) 15851A>G (4/51)
10104C>T (5/50) 194C>T(14/41) 15927G>A (4/51)
             M7b2                D4a 199T>C (18/37) 14605A>G(9/46) 16243T>C (4/51)
         (7/55: 13%)           (8/55:15%)
             D4b2a              D4b2b                B5b
          (5/55: 9%)          (9/55: 16%)           (4/55: 7%)
 
(B) Centenarians 
 
          L3
489T>C (25/22) 8701A>G (24/23)
10400C>T (25/22) 9540T>C (25/22)
14783T>C (25/22) 10398A>G (28/19)
15043G>A (25/22) 10873T>C (25/22)
15301G>A (25/22)
          M
           N
16362T>C (27/20)
16519T>C (27/20)
709G>A (17/30) 16519T>C(27/20)
4833A>G (10/37) 4883C>T(13/37) 12705C>T (35/12) 5417G>A (7/40)
5108T>C (12/35) 5178C>A(13/27) 16223C>T (34/13) 5147G>A (9/38)
14569G>A (12/35)
                D 3970C>T(5/42) 16519T>C (27/20) 150C>T(10/37) 10607C>T (4/43)
8200T>C(4/43) 16519T>C (27/20) 13928G>C(5/42) 16217T>C (5/42) 5231G>A(2/45) 11016G>A (4/43)
15323G>A(4/43) 5601C>T (8/39) 3010G>A(9/38) 16304T>C(5/42) 15346G>A (5/42) 12358A>G(2/45) 13183A>G (4/43)
15497G>A(4/43) 13563A>G (8/39) 8414C>T(9/38) 6392T>C(5/42) 3497C>T (5/42) 12372G>A(2/45) 14893A>G (4/43)
7867C>T(4/43) 7600G>A (8/39) 14668C>T(9/38) 10310G>A(8/39) 709G>A (17/30) 16262C>T(2/45)
9377A>G (8/39) 6962G>A(5/42)         N9b1
G1 9575G>A (8/39)               D4 10609T>C(5/42)         B4c1             N9a       (4/47: 9%)
(4/47: 9%) 14200T>C (8/39)          (9/47:19%) 12406G>A(6/41)      (5/47: 11%)         (2/47: 4%)
16278C>T (8/39) 12882C>T(5/42)
        G2a                F1
     (8/47: 17%)           (5/42:11%)
 
(C) AD patients 
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          L3
489T>C (36/11) 8701A>G (36/11)
10400C>T (36/11) 9540T>C (36/11)
14783T>C (36/11) 10398A>G (40/7)
15043G>A (36/11) 10873T>C (36/11)
15301G>A (36/11)
          M
           N
4715A>G (2/45) 16362T>C (32/15)
7196C>A (2/45) 16519T>C (29/18)
8584G>A (6/41) 709G>A (12/35) 16519T>C (29/18) 12705C>T (39/8)
15487A>T (2/45) 4833A>G (5/42) 4883C>T (26/21) 16223C>T (40/7)
16298T>C (2/45) 5108T>C (5/42) 5178C>A (26/21) 16519T>C (29/18)
6179G>A (2/45) 14569G>A (5/42)
8684C>T (2/45) 16519T>C (29/18)           D 3970C>T (4/43) 709G>A (12/35) 5417G>A(3/44)
14470T>C (6/41) 13928G>C (4/43) 8584G>A (6/41) 5147G>C(3/44)
16319G>A (6/41)           G 3010G>A (22/24) 150C>T(9/38) 16304T>C (4/43) 9950T>C (4/43) 16519T>C(27/18)
16519T>C (29/18)      (5/47: 11%) 8414C>T (25/24) 1107T>C(4/43) 6392T>C (4/43) 10398A>G (40/7) 10607C>T(3/44)
6719T>C (3/44) 14668C>T (22/25) 5301A>G(4/43) 10310G>A (4/43) 16140T>C (5/42) 11016G>A(3/44)
16311T>C (6/41) 10397G>A(3/44) 6962G>A (4/43) 204T>C (3/44) 13183A>G(3/44)
          D4 9180A>G(3/44) 10609T>C (2/43) 1598G>A (3/44) 14893A>G(3/44)
       M8a1     (22/47: 47%) 752C>T(3/44) 12406G>A (4/43) 8829C>T (3/44)
     (2/47: 4%) 11944T>C(3/44) 12882C>T (3/44) 12361A>G (3/44)           N9b1
12026A>G(3/44) 15223C>T (3/44) (3/47:6%)
           F1 15508C>T (3/44)
D5a (3/47: 6%) 15662A>G (3/44)
        (3/47:6%) 15851A>G (3/44)
15927G>A (3/44)
16243T>C (3/44)
          B5b
(3/47: 6%)(D) T2D patients  
 
489T>C (17/0)
10400C>T (17/0)
14783T>C (17/0)
15043G>A (17/0)
16362T>C (16/1)
16519T>C (0/17)
4883C>T (17/0)
5178C>A (17/0)
3010G>A (17/0)
8414C>T (17/0)
14668C>T (17/0)
8701A>G (12/5) 8020G>A (10/7)
4343A>G (5/12)
13104A>G (5/12) 10181C>T (4/13) 1382A>C(6/11)
15518C>T (5/12) 15440T>C (4/13) 8964C>T(6/11)
16278C>T (5/12) 15951A>G (4/13)
16319G>A (4/13)
431C>T (4/13)       (6/17: 35%)
     (5/17: 29%) 6689C>T (4/13)
16287C>T (4/13)
16399A>G (3/14)
    (4/17: 24%)
L3
M
D
D4g
D4b1b
D4b2
 
(E) Non-obese young males 
Fig. 3. Associations between haplogroups and the mtSNPs of the persons whose 
probabilities of becoming PD patients are greater than 50%. (B) Centenarians, (C) AD 
patients, (D) T2D patients, (E) Non-obese young males. 
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Fuku et al. (2007) reported that the mitochondrial haplogroup F in Japanese individuals had 
a significantly increased risk of type 2 diabetes mellitus (T2DM) (odds ratio 1.53, P=0.0032) 
using hospital based sampling data for large-scale association study (Fuku et al., 2007). They 
indicated that there were three mtSNPs in the haplogroup F – 3970C>T, 13928G>C, and 
10310G>A. In the present analysis, the risk of T2D patients for the haplogroup F1 was 
approximately 13% (Fig. 2D). Other haplogroups related to the risk of T2D patients were 
B5b (20%), M8a1 (13%), D4 (13%) and G (13%) (Fig. 2D and Table 2). There were therefore 
big differences between the analyses of Fuku et al. (2007) and the results reported here. The 
significantly increased risk of T2DM was the haplogroup F in Fuku et al. (2007), whereas 
that of the results obtained was the haplogroup B5b. Although Fuku et al. (2007) indicated 
that the haplogroup F was the increased risk of T2DM, the F has four sub-haplogroups F1, 
F2, F3, and F4. In the work reported here, the only haplogroup F1 was obtained by the 
modified clustering method. The haplogroup F by Fuku et al. (2007) was characterized by 
three mtSNPs—3970C>T, 13928G>C, and 10310G>A, whereas the haplogroup F1 by the 
proposed method was featured by many mtSNPs—3970C>T, 13928G>C, 16304T>C, 
6392T>C, 10310G>A, 6962G>A, 10609T>C, 12406G>A, and 12882C>T (Tanaka et al., 2004) 
(Fig. 2D). Furthermore, as Saxena et al. (2006) reported that there was no evidence of 
association between common mtDNA polymorphism and type 2 diabetes mellitus, the 
results obtained may indicate new findings for T2D patients (Saxena et al., 2006). 
In addition, Alexe et al. (2007) reported the associations between Asian haplogroups and the 
longevity of Japanese people using the same GiiB data (Alexe et al., 2007). They showed the 
enrichment of longevity phenotype in mtDNA haplogroups D4b2b, D4a, and D5 in the 
Japanese population using statistical techniques (t-test and P-value). However, the results 
here showed that the haplogroups M7b2, D4b2a, and B5b were associated with Japanese 
centenarians. There is therefore no common haplogroup in both methods. Alexe et al. (2007) 
showed that the haplogroup D5 was characterized by mtSNPs 11944T>C, 12026A>G, 
1107T>C, 5301A>G, 10397A>G, and 752C>T, whereas there was no frequency in the 
corresponding mtSNPs in the present analysis. Although they reported that the centenarian 
enrichment was not found in the haplogroup D4b2a, the present results showed that the 
corresponding D4b2a was characterized by many mtSNPs with a frequency of 27% (Fig. 2B). 
Although Alexe et al. (2007) described that there was no haplogroup having mtSNPs 
significantly enriched in centenarians other than D mega-group in M macrohaplogroup, the 
present analysis indicated that the haplogroup M7b2 was characterized by many mtSNPs 
(Fig. 2B and 3B). They also reported that there was no enrichment haplogroup for 
centenarians in macrohaplogroup N, whereas the haplogroup B5b obtained by the proposed 
method also had many mtSNPs enriched in centenarians (Figs. 2B and 3B).  
Bilal et al. (2008) reported the haplogroup D4a was a marker for extreme longevity in Japan 
by analyzing the complete mtDNA sequences from 112 Japanese semi-supercentenarians 
(aged over 105 years old) combined with previously published data (Bilal et al., 2008). These 
semi-supercentenarians were also examined using the proposed method. Since the 
predicted probabilities of individual clusters for the semi-supercentenarians were lower 
than those of the centenarians, 43 individuals with predicted probabilities over 46% (the 
average is 54%) were selected. The obtained results were the haplogroups D4a (30%), B4c1a 
(14%), M7b2 (12%), F1 (9%), M1 (7%) and B5b (2%) shown in Fig. 4. As the highest 
haplogroup was D4a, this was the same as the marker described by Bilal et al. (2008). 
However, there are other haplogroups indicating the characteristics of semi-
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supercentenarians. This means that other haplogroups also have the possibilities of 
becoming semi-supercentenarians. The common haplogroups between the centenarians and 
semi-supercentenarians were M7b2 and B5b. 
 
489T>C (22/21) 8701A>G (21/22)
10400C>T (21/22) 9540T>C (21/22)
14783T>C (21/22) 10398A>G (23/20)
15043G>A (21/22) 10873T>C (21/22)
15301G>A (21/22)
16311T>C (10/33) 6455C>T (5/38) 16362T>C (17/26)
195T>C (10/33) 9824T>C (5/38) 16519T>C (34/9) 16519T>C (34/9)
195T>C (1/42) 199T>C (9/34) 4883C>T (13/30) 12705C>T (26/17)
6680T>C (5/38) 4071C>T (5/38) 5178C>A (13/30) 16223C>T (28/15)
16249T>C (3/40) 150C>T (7/36) 16519T>C (34/9)
4048G>A (5/38)
4164A>G (5/38) 709G>A (9/34) 3970C>T (7/36) 6217T>C (9/34)
(3/43: 7%) 5351A>G (5/38) 3010G>A (13/30) 8584G>A (1/42) 13928G>C (7/36) 1119 T>C (6/37)
5460G>A (5/38) 8414C>T (13/30) 9950T>C (1/42) 6392T>C (7/36) 15346G>A (6/37)
6680T>C (5/38) 14668C>T (13/30) 10398A>G (23/20) 10310G>A (11/32) 3497C>T (6/37)
7684T>C (5/38) 16140T>C (2/41) 6962G>A (4/39) 709G>A (9/34)
7853G>A (5/38) 152T>C (22/21) 204T>C (3/40) 10609T>C (4/39) 10310G>A (11/32)
12405C>T (5/38) 3206C>T (13/30) 1598G>A (1/42) 12406G>A (4/39) 16311T>C (10/33)
12811T>C (5/38) 14979T>C (13/30) 8829C>T (1/42) 12882C>T (4/39)
16297T>C (5/38) 16129G>A (25/18) 12361A>G (1/42)
16129G>A (25/18) 8473T>C (13/30) 15223C>T (1/42) (6/43: 14%)
10345T>C (5/38) 16519T>C (34/9) 15508C>T (1/42) (4/43: 9%)
16298T>C (5/38) 10410T>C (13/30) 15662A>G (1/42)
15851A>G (1/42)
3206C>T (13/30) 15927G>A (1/42)
(5/43: 12%) 16243T>C (1/42)
(13/43: 30%)
(1/43: 2%)
L3
M
M7b2
D
D4a
N
B5b
M1
F1
B4c1a
 
Fig. 4. Associations between Asian/Japanese haplogroups and mtSNPs of semi-
supercentenarians. 
3.3 Differences between statistical technique and the modified RBF method 
Although the haplogroups of the PD patients were obtained by the modified RBF method, 
there are clear differences between the previously reported statistical technique and the 
method described here. As the previously reported methods analyzed the relations between 
mtSNPs and Japanese PD patients, centenarians, AD patients, T2D patients, or semi-
supercentenarians using standard statistical techniques (Alexe et al., 2007; Fuku  et al., 2007; 
Bilal et al., 2008), they could not indicate mutual relations among the other classes of 
people—centenarians, AD patients, T2D patients and healthy non-obese young males. On 
the other hand, the proposed method was able to show differences and mutual relations 
among these classes of people. In addition, the prediction probabilities of associations 
between mtSNPs and these classes of people cannot be obtained by the statistical techniques 
used in the previous methods, whereas the method proposed is able to compute them based 
on learning mtSNPs of individual classes. 
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It is considered that the relations among individual mtSNPs for these classes of people 
should be analyzed as mutual mtSNP connections in the entire mtSNPs. A learning method, 
a RBF network, was therefore adopted for extracting individual characteristics from the 
entire mtSNPs, although the previous methods used standard statistical techniques.  
 
          Statistical technique Proposed method
Technique
Relative relations between
target and normal data
Supervised learning (RBF) by
using correct and incorrect data
Analysis position
Each locus of mtDNA
polymorphisms
(independent position)
Entire loci of mtDNA
polymorphisms
(succesive positions)
Input
(required data)
Target  (individual cases) and
control (normal data)
Correct (individual cases) and
incorrect (others except correct)
Output (results) Odds ratio or relative risk Clusters with predictions
Analysis
Check odds ratio or relative
risk at each position
Check individuals in clusters
based on prediction probabilities
 
Table 2. Differences between the statistical technique and the proposed (modified RBF) 
method 
The differences between standard statistical technique and the proposed method are listed 
in Table 2. In the statistical technique, the analysis of odds ratios or relative risks is based on 
the relative relations between target and control data at each polymorphic mtDNA locus. In 
the modified RBF method, on the other hand, clusters indicating predicted probabilities are 
examined on the basis of the RBF using correct and incorrect data for the entire polymorphic 
mtDNA loci. The statistical technique determines characteristics of haplogroups using 
independent mtDNA polymorphisms that indicate high odds ratios, whereas the modified 
RBF method determines them by checking individuals with high predicted probabilities. 
This means that the statistical technique uses the results of independent mutation positions, 
whereas the modified RBF method uses the results of entire mutation positions. As there are 
the differences between the two methods, which method is better depends on future 
research. Furthermore, the method described here may have possibilities for use in the 
initial diagnosis of various diseases or longevity on the basis of the individual predicted 
probabilities. 
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Parkinson's disease (PD) results primarily from the death of dopaminergic neurons in the substantia nigra.
Current PD medications treat symptoms; none halt or retard dopaminergic neuron degeneration. The main
obstacle to developing neuroprotective therapies is a limited understanding of the key molecular mechanisms
that provoke neurodegeneration. The discovery of PD genes has led to the hypothesis that misfolding of
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in elucidating important aspects of the disease, such as selective vulnerability of substantia nigra dopaminergic
neurons to the degenerative process.
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